Abstract 1679
Background
Human papillomavirus 16 (HPV16) elicits cervical cancers and provides an ideal target for T cell-based immunotherapy. Although engineered T cell therapies delivered unprecedented successes in hematological cancers, treating solid cancers has been suboptimal. One key mechanism of tumor-elicited suppression is the PDL1-PD1 checkpoint which blocks T cell activation. Therefore, TCR-T cells armored with checkpoint blockades may further enhance the efficacy of TCR-T in solid cancers.
Methods
HPV16+HLA-A2+ Stage IV cervical cancer patients were consented and enrolled to a two-arm study: Arm 1 is a mono-treatment with HPV16 TCR-T, and, Arm 2 is a treatment with anti-PD1 scFv expressing HPV16 TCR-T cells. PBMCs were collected from patient by lymphocyte apheresis and a TCR targeting HLA-A2-presented E6 epitope was retrovirally transduced. This study is designed for dose escalation at three levels: 5 × 106/kg, 1 × 107/kg, and 5 × 107/kg. Initial safety and efficacy were monitored at day 7, 14, 28 post treatment, followed by long-term monthly monitoring for up to two years.
Results
By the date of submission, five patients have been treated in Arm 1: two were infused with 5 × 106/kg dose, and three were infused with 1 × 107/kg dose. Adverse effects include leukocytopenia (100%), anemia (100%), fatigue (60%), fever (40%) and thrombocytopenia (40%). One patient (20%) had Grade 4 leukocytopenia. No CRS was observed. For all five patients, TCR-T cells were engrafted, and expanded with peak responses during day 7 to 14 post-infusion. At 28 days post-infusion, three patients (60%) were assessed as SD, one patient (20%) was assessed as PD, and one patient was absent for follow-up. Two patients have been recruited for arm 2. One patient received 5 × 106/kg and one received 1 × 107/kg of anti-PD1 armored TCR-T cells. The low dose patient was assessed as SD at both day 28 and month 2 post treatment.
Conclusions
With mild and manageable sides effects, both mono and anti-PD1-armored E6-TCR-T therapies demonstrated to be safe at up to 1 × 107/kg dosage. T cells were stimulated in patients and clinical responses can be identified. These results warrant further evaluation of the safety and efficacy at higher doses.
Clinical trial identification
NCT03578406.
Editorial acknowledgement
Legal entity responsible for the study
Xinqiao Hospital, Third Militrary Medical University and TCRCure Biopharma Corp.
Funding
TCRCure Biopharma Corp.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3073 - 1 patient 3 different advance Ca nurse’s roles: symptom management&continuum care through a joint approach in a clinical case
Presenter: Catarina Almeida
Session: Poster Display session 3
Resources:
Abstract
4527 - Identification of malnutrition risk factors in patients with cancer in the first nursing visit
Presenter: Amaia Valverde
Session: Poster Display session 3
Resources:
Abstract
2904 - Engaging Cancer Survivors, Healthcare Providers and Advocates in The Development of a Colorectal Cancer Survivorship Information Resource: A Participatory Action Research Study
Presenter: Amanda Drury
Session: Poster Display session 3
Resources:
Abstract
3435 - Medical nurses’ experiences of the care-needs of adult patients with a primary brain tumour
Presenter: Jamila Mohammed
Session: Poster Display session 3
Resources:
Abstract
857 - Feasibility and acceptability of a mHealth intervention to increase colonoscopy uptake among Chinese first-degree relatives: a pilot cluster randomized controlled trial
Presenter: Yang Bai
Session: Poster Display session 3
Resources:
Abstract
1087 - Cancer patient participation and compliance in microbiome sample collection: an oncology research nurse’s experience
Presenter: Julie Malo
Session: Poster Display session 3
Resources:
Abstract
2783 - Implementing Digital Individual Care plans for Patients with Head and Neck cancer- Challenges and opportunities
Presenter: Helena Ullgren
Session: Poster Display session 3
Resources:
Abstract
1152 - The Effect of the Short-term and Long-term Compassion Fatigue Resiliency Program on the Quality of Life, Perceived Stress and Psychological Resilience of Oncology-Hematology Nurses
Presenter: Tugba Pehlivan
Session: Poster Display session 3
Resources:
Abstract
1172 - Competing risk analyses of overall survival and cancer-specific survival in patients with orbital rhabdomyosarcoma after surgery: a large cohort study
Presenter: Yu Zhang
Session: Poster Display session 3
Resources:
Abstract
5949 - Communication of genetic information to family members in hereditary cancers and healthcare providers’ role
Presenter: Carla Pedrazzani
Session: Poster Display session 3
Resources:
Abstract